Watch us on YouTube Live at 8:30AM EST
Tesla Inc – Continuing its impressive recent run in the premarket, approaching $850 in early trading Monday ahead of Q3 results due aftermarket Wednesday. The company also recently posted better than expected Q3 delivery numbers with most analysts quick to suggest the results will likely reflect the favorable impact of the rising Model 3/Y deliveries, which form a major chunk of the automaker’s overall deliveries.
Apple Inc – On watch today ahead of the company’s “Unleashed” event set to kick off at 1pm est this afternoon, recent speculation suggests Apple could reveal a higher-res miniLED display expected for new MacBook Pros. These new, more powerful MacBook Pros also come in 14- and 16-inch screen sizes, and, may have SD readers and HDMI and MagSafe ports. And possibly new AirPods as well.
Virgin Galactic – Lower in early trading after Friday’s selloff, UBS is the first investment bank to downgrade the stock following Friday’s announcement to a “Sell” from “Neutral” and cut its PT to $15.
Gitlab Inc – Impressive two debut for the code sharing platform’s stock last week, looking to extend its rally trading near Friday’s highs premarket, the company debuted on the Nasdaq Thursdya valued at $14.9 bln.
Fuelcell Energy – Up sharply premarket after rallying into the close Friday on increased social media mentions. The small cap, renewable energy firm currently has a 15.5% short interest.
Netflix Inc – Set to report this week, Bloomberg quoting an internal document is reporting the company is now extimating it’s hit series “Squid Game” could bring in as much as $900m while costing just $21m to produce.
Adamis Pharmaceuticals – Higher after announcing the U.S. Food and Drug Administration (FDA) has approved Adamis’ ZIMHI™ (naloxone HCL Injection, USP) 5 mg/0.5 mL product. ZIMHI is a high-dose naloxone injection product FDA-approved for use in the treatment of opioid overdose.
ION Geophysical – Micro cap oil services company trading higher after announcing preliminary third quarter 2021 revenues of $44 – 45 million, an increase of ~125% sequentially, driven by 3D strategy.
Oyster Point Pharma – Small cap biotech higher after recieving FDA approval for its nasal spray treatment for dry eye disease.